Skip to main content
. 2006 May;168(5):1631–1641. doi: 10.2353/ajpath.2006.050521

Figure 3.

Figure 3

Brk expression and activation status in normal activated and malignant T-cell populations. A: Western blot: expression of Brk by T-cell-rich PBMCs, either resting or activated by mitogen (PHA) or anti-CD3/CD28 antibody combination and by patient-derived CTCL cells. B: Kinase activity assay: enzymatic activity of Brk immunoprecipitated from the resting and PHA-activated PBMCs and CTCL cells. Immunoprecipitates from the 2A T-cell line lysate untreated or treated with a Brk-blocking peptide served as controls.